Topics

KOL Perspectives: BTK Inhibitors in RA [Report Updated: 06082018] Prices from USD $2125

04:41 EST 29 Nov 2018 | BioPortfolio Report Blog

KOL Perspectives: BTK Inhibitors in RA


Summary


This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.


Questions topics

Awareness and potential of BTK inhibitors in RA

Perceptions of BMS986142's Phase IItrial design

Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA


Key Highlights


Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS986142, despite its lack of Phase II data

KOLs were divided over BMS986142's ability to achieve ACR70 by Week 12 in a refractory patient population

For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs.


In total, we conducted interviews with 10 KOLs

5 Europebased 5 N. Americabased

Interviews performed during Q2 2018


KOL data is analyzed to produce

Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on BTK Inhibitors in RA

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of RA

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: BTK Inhibitors in RA [Report Updated: 06082018] Prices from USD $2125

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: BTK Inhibitors in RA [Report Updated: 06082018] Prices from USD $2125"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...